Shanghai Xuerong BiotechnologyLtd Yönetim

Yönetim kriter kontrolleri 2/4

Shanghai Xuerong BiotechnologyLtd CEO'su Yongping Yang, Apr2022 tarihinde atandı, in görev süresi 2.58 yıldır. şirketin hisselerinin 21.57% doğrudan sahiptir ve bu hisselerin değeri CN¥ 426.12M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.6 yıl ve 1.9 yıldır.

Anahtar bilgiler

Yongping Yang

İcra Kurulu Başkanı

CN¥1.0m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	2.6yrs
CEO sahipliği	21.6%
Yönetim ortalama görev süresi	2.6yrs
Yönetim Kurulu ortalama görev süresi	1.9yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yongping Yang (55 yo)

2.6yrs

Görev süresi

CN¥1,026,600

Tazminat

Mr. Yongping Yang serves as Chairman of Shanghai Xuerong Bio-Technology Co., Ltd. and serves as its General Manager since April 12, 2022. Mr. Yang serves as Honorary President of Fujian Chamber of Commerce...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yongping Yang	Chairman & GM	2.6yrs	CN¥1.03m	21.57% CN¥ 426.1m
Yong Lu	Deputy GM & Non-Independent Director	no data	CN¥845.30k	Veri yok
Wei Guo	Deputy GM & Non-Independent Director	2.6yrs	CN¥1.01m	0.012% CN¥ 237.6k
Yongkang Gu	Board Secretary	5.9yrs	CN¥717.00k	0.0059% CN¥ 115.8k

2.6yrs

Ortalama Görev Süresi

48.5yo

Ortalama Yaş

Deneyimli Yönetim: 300511 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.6 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yongping Yang	Chairman & GM	no data	CN¥1.03m	21.57% CN¥ 426.1m
Yong Lu	Deputy GM & Non-Independent Director	2.5yrs	CN¥845.30k	Veri yok
Wei Guo	Deputy GM & Non-Independent Director	1.9yrs	CN¥1.01m	0.012% CN¥ 237.6k
Lihua Mao	Non-Employee Supervisor	7.3yrs	Veri yok	Veri yok
Jianchun Huang	Independent Director	4yrs	CN¥120.00k	Veri yok
Jie Li	Director	1.7yrs	CN¥773.50k	0.0096% CN¥ 190.0k
Xueyao Li	Independent Director	1.5yrs	CN¥120.00k	Veri yok
Danmeng Li	Independent Director	1.3yrs	CN¥42.60k	Veri yok

1.9yrs

Ortalama Görev Süresi

49.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300511 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.9 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Shanghai Xuerong BiotechnologyLtd Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new directors

Shanghai Xuerong Biotechnology Co.,Ltd., Annual General Meeting, May 17, 2024

Shanghai Xuerong Biotechnology Co.,Ltd. Approves Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Shanghai Xuerong Biotechnology Co.,Ltd. Approves By-Election of Directors

Recent updates

Third quarter 2024 earnings released: CN¥0.041 loss per share (vs CN¥0.38 loss in 3Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.34 loss in 2Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) agreed to acquire remaining 31.03% stake in Lintao Xuerong Biotechnology Co., Ltd. from Gansu Green and Ecological Industry Development Government Guided Fund Management Co., Ltd. for approximately CNY 45 million.

High number of new directors

Shanghai Xuerong Biotechnology Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

New minor risk - Share price stability

Shanghai Xuerong Biotechnology Co.,Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.01 (vs CN¥0.45 in 1Q 2023)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New major risk - Financial position

Third quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.12 profit in 3Q 2022)

Shanghai Xuerong Biotechnology Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

Second quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.30 loss in 2Q 2022)

Shanghai Xuerong Biotechnology Co.,Ltd. Approves Board Appointments

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.11 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.30 loss per share (vs CN¥0.37 loss in 2Q 2021)

Shanghai Xuerong Biotechnology Co.,Ltd. Approves By-Election of Directors

Shanghai Xuerong Biotechnology Co.,Ltd. Announces Final Cash Dividend Proposal for 2021

First quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.24 in 1Q 2021)

Now 21% undervalued

Second quarter 2021 earnings released: CN¥0.37 loss per share (vs CN¥0.033 loss in 2Q 2020)

Shanghai Xuerong Biotechnology Co.,Ltd. Announces to Implement Final Cash Distribution Plan for 2020, Payable on 14 May 2021

Shanghai Xuerong Biotechnology Co., Ltd. Approves Cash Dividend for the Year 2020

First quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.40 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.57 (vs CN¥0.51 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥10.82

New 90-day low: CN¥12.17

New 90-day low: CN¥13.30

New 90-day low: CN¥13.81

New 90-day low: CN¥14.39

Shanghai Xuerong Biotechnology Co.,Ltd. announced that it expects to receive CNY 2.25 billion in funding

Third quarter earnings released

First half earnings released

New 90-day high - CN¥19.22

Shanghai Xuerong Biotechnology Co.,Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥18.35

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş